NUI Galway Researchers Discover New Risk Factor for Schizophrenia

Jan 31 2014 Posted: 09:51 GMT

Research led by NUI Galway and the University of Aberdeen published in the Journal of Cell Science

Professor Sanbing Shen of the Regenerative Medicine Institute (REMEDI) at NUI Galway has led a multi-institutional study which has identified a novel rare risk factor linked with mental illnesses such as schizophrenia.

Schizophrenia is a disorder which although many genetic risk factors have been identified, no effective treatment is available. Professor Shen and his colleagues have identified for the first time that changes in a little known gene called ULK4 were observed in individuals with schizophrenia.

Unlike many other genetic studies, Shen and colleagues have also characterised how ULK4 functions in the brain. When levels of ULK4 are decreased, neuronal (brain) cells tend to function less well, leading to reduced synaptic function and other changes which are also known as risk factors of schizophrenia.

The scientists were also able to show that ULK4 is essential for the formation of the nerve fibres which connect the two sides of our brains. The research not only demonstrates that ULK4 dysregulation is a risk factor for schizophrenia, but also that ULK4 plays an essential role in proper brain formation.

The findings published in the Journal of Cell Science (Thursday, 30th January) were supported by genetic data provided by the International Schizophrenia Consortium, and confirmed using new data generated from other mental illness groups including autism, major depression, and bipolar disorder.

Follow up studies already underway in NUI Galway will lead to a better understanding of the disease and how drugs may be developed to target ULK4 for the treatment of mental illness.

The research was funded by Science Foundation Ireland, NUI Galway, Cunningham Trust, Scottish Universities Life Sciences Alliance, Medical Research Scotland and the University of Aberdeen.

Link to Journal of Cell Science http://jcs.biologists.org/content/127/3/630

-ends-

Marketing and Communications Office

Previous